30-Day Post-Discharge Prophylaxis with Rivaroxaban Prevents Porto-mesenteric Venous Thrombosis Following Laparoscopic Sleeve Gastrectomy

Swartz, Daniel E.; Hood, Lisa; Swartz, Devin R.; Gupta, Sachin

doi:10.1007/s11695-023-06471-z

Cited by 7 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with PVT who undergo liver transplant (LT) display an increased risk of complications. Cryptogenic cirrhosis, obesity, fatty liver disease, type 2 diabetes mellitus (T2DM), or ascites have been related to an increased risk of post-transplant PVT in patients on the transplantation network waitlist [ 149 ].…”

Section: Liver Transplant and Pvtmentioning

confidence: 99%

Portal Vein Thrombosis: State-of-the-Art Review

Boccatonda,

Gentilini,

Zanata

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Portal vein thrombosis (PVT) is a rare disease with an estimated incidence of 2 to 4 cases per 100,000 inhabitants. The most common predisposing conditions for PVT are chronic liver diseases (cirrhosis), primary or secondary hepatobiliary malignancy, major infectious or inflammatory abdominal disease, or myeloproliferative disorders. Methods: PVT can be classified on the basis of the anatomical site, the degree of venous occlusion, and the timing and type of presentation. The main differential diagnosis of PVT, both acute and chronic, is malignant portal vein invasion, most frequently by hepatocarcinoma, or constriction (typically by pancreatic cancer or cholangiocarcinoma). Results: The management of PVT is based on anticoagulation and the treatment of predisposing conditions. The aim of anticoagulation in acute thrombosis is to prevent the extension of the clot and enable the recanalization of the vein to avoid the development of complications, such as intestinal infarction and portal hypertension. Conclusions: The treatment with anticoagulant therapy favors the reduction of portal hypertension, and this allows for a decrease in the risk of bleeding, especially in patients with esophageal varices. The anticoagulant treatment is generally recommended for at least three to six months. Prosecution of anticoagulation is advised until recanalization or lifelong if the patient has an underlying permanent pro-coagulant condition that cannot be corrected or if there is thrombosis extending to the mesenteric veins.

show abstract

Section: Liver Transplant and Pvtmentioning

confidence: 99%